gicaxitinib

Gicaxitinib (also known as JX05) is an orally bioavailable small molecule inhibitor of Janus kinase 2 (JAK2) being developed by Zhejiang Gicaxy Pharmaceutical. It is primarily investigated for the treatment of myeloproliferative neoplasms, specifically intermediate- to high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. Gicaxitinib is designed to inhibit the JAK-STAT signaling pathway, which is constitutively active in these conditions due to mutations such as JAK2 V617F. Clinical development includes its use as a monotherapy and in combination with other agents, such as the XPO1 inhibitor selinexor, particularly in patients who have relapsed on or are refractory to prior JAK inhibitor therapy like ruxolitinib.

Other names

gicaxitinib hydrochlorideJX05 hydrochlorideJX-05 hydrochlorideJX 05 hydrochloride